Recursion's CEO, Dr. Chris Gibson, will update on clinical developments at the JP Morgan Healthcare Conference on January 13.
Quiver AI Summary
Recursion, a clinical stage TechBio company focused on improving lives through biology, announced that its co-founder and CEO, Chris Gibson, PhD, will present at the 43rd Annual JP Morgan Healthcare Conference in San Francisco on January 13, 2025, at 7:30 am PT. During his presentation, he will provide updates on the company's clinical pipeline, partnerships, and developments following Recursion's recent merger with Exscientia. The presentation will be accessible on Recursion’s website for 30 days after the event.
Potential Positives
- Recursion's CEO, Chris Gibson, will present at a prominent industry event, the 43rd Annual JP Morgan Healthcare Conference, enhancing the company's visibility in the healthcare sector.
- The presentation will cover updates on Recursion's clinical pipeline and partnerships, showcasing advancements and potential growth opportunities in the company's operations.
- The availability of the presentation on Recursion’s website for 30 days allows for extended audience engagement and interest in the company’s developments.
- The announcement highlights the strategic importance of the recent combination with Exscientia, indicating ongoing efforts to strengthen company capabilities and innovation in the TechBio space.
Potential Negatives
- CEO Chris Gibson's presentation follows a recent combination with Exscientia, which may raise concerns about the effectiveness of this merger and its impact on the company's stability and future direction.
- The focus on updates from Recursion's clinical pipeline implies potential ongoing challenges or delays in development, which could be a negative signal to investors regarding the company's progress.
- The need for a formal presentation at a major healthcare conference might indicate that the company is seeking to reassure stakeholders about its viability and future plans amid uncertainties.
FAQ
What is the purpose of Recursion's presentation at the JP Morgan Healthcare Conference?
Recursion's CEO will present updates on the company's clinical pipeline, partnerships, and platform advancements.
When is Dr. Chris Gibson's presentation scheduled?
The presentation is scheduled for January 13, 2025, at 7:30am PT (10:30am ET).
Where will the JP Morgan Healthcare Conference be held?
The conference will be held at the Westin St. Francis in San Francisco.
How can I access the presentation after it occurs?
The presentation will be available on Recursion's website for at least 30 days after the event.
What recent event is Recursion discussing at the conference?
Recursion will discuss the company's recent combination with Exscientia during the presentation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RXRX Insider Trading Activity
$RXRX insiders have traded $RXRX stock on the open market 36 times in the past 6 months. Of those trades, 0 have been purchases and 36 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- CHRISTOPHER GIBSON (Chief Executive Officer) has traded it 12 times. They made 0 purchases and 12 sales, selling 310,000 shares.
- MICHAEL SECORA (Chief Financial Officer) has traded it 10 times. They made 0 purchases and 10 sales, selling 150,000 shares.
- BLAKE BORGESON has traded it 10 times. They made 0 purchases and 10 sales, selling 114,470 shares.
- TINA MARRIOTT (President and COO) has traded it 4 times. They made 0 purchases and 4 sales, selling 24,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RXRX Hedge Fund Activity
We have seen 151 institutional investors add shares of $RXRX stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARK INVESTMENT MANAGEMENT LLC added 4,626,268 shares (+16.4%) to their portfolio in Q3 2024
- STATE STREET CORP added 4,120,685 shares (+47.1%) to their portfolio in Q3 2024
- BLACKROCK, INC. added 3,432,635 shares (+19.8%) to their portfolio in Q3 2024
- LAURION CAPITAL MANAGEMENT LP removed 2,901,134 shares (-100.0%) from their portfolio in Q3 2024
- VANGUARD GROUP INC added 2,716,252 shares (+12.6%) to their portfolio in Q3 2024
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 2,315,000 shares (+inf%) to their portfolio in Q3 2024
- BAILLIE GIFFORD & CO removed 1,350,066 shares (-5.1%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Salt Lake City, UT, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announces that co-founder and CEO Chris Gibson, PhD will present at the upcoming 43rd Annual JP Morgan Healthcare Conference in San Francisco.
On Monday, January 13, 7:30am PT (10:30am ET), at the Westin St. Francis in the Elizabethan Room A/B, Dr. Gibson will present updates on Recursion’s latest clinical pipeline, partnerships, and platform following the company’s recent combination with Exscientia. The talk will be available on Recursion’s website for at least 30 days following the presentation here: https://ir.recursion.com/news-events/events-presentations .
